This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Molecular Diagnostics Market & Forecast (By Application, Technology, Countries, Companies & Clinical Trials) To 2017: Global Analysis

Molecular Diagnostics Market - Geographical Analysis

United States molecular diagnostic market is expected to be more than double by 2017 from its current market in 2012.• Europe stands at the second position in the global molecular diagnostic market. • China, Japan and India are expected to stand at 3rd, 4th and 5th slot respectively.• The Mexico molecular diagnostics market is predicted to grow at a CAGR of 17% between 2012 and 2017.

Molecular Diagnostics Market – Company Wise Analysis

• The Roche molecular diagnostic share is greater than the combined share of Myriad Genetics and Qiagen which holds the 2nd and 3rd position respectively. • Abbott stands at the 4th spot and expected to generate sales worth US$ XXXX Million by the year 2017.• The Myriad Genetics molecular diagnostic sales were worth US$ XXXX Million in 2012.

Renub Research study titled "Molecular Diagnostics Market & Forecast (By Application, Technology, Countries, Companies & Clinical Trials) to 2017: Global Analysis" provides a comprehensive assessment of the fast-evolving, high-growth Global Molecular Diagnostics market.

This 158 page report with 81 Figures and 23 Tables studies the Global Molecular Diagnostics: 1) Market and Forecast 2) Application Wise Market & Forecast 3) Geographical Market & Forecast 4) Technology Wise Market & Forecast 5) Company Wise molecular Diagnostics sales & Forecast 6) Molecular Diagnostic & Personalized Medicines 7) Clinical trials In Molecular Diagnostics Landscape.

The Report Covers the Following Points

• Global Molecular Diagnostic Market (2010-12) and Forecast (2013 to 2017)• Global Molecular Diagnostic Application Segment (Infectious Disease Testing, Virology Testing, HAI Testing, HPV Testing, Critical Care Infectious Testing, Blood Screening, Genetic Testing, Oncology Testing, Tissue Typing, Cardiovascular Disease Testing, Neurological Disorders Testing, Food Pathogen Detection Testing & Others) Market (2010-2012) and Forecast (2013 to 2017)• Molecular Diagnostic Technology Segment (PCR Based Test, PCR Related Technologies , Non-PCR Test, Fish & Innovations Testing, Biochips/Microarrays, Biosensors, Molecular Imaging, & Other Technologies) Market (2010-2012) and Forecast (2013 to 2017) • Molecular Diagnostic Geographical Distribution (US, Europe, China, Japan, India, Brazil, Mexico, South Korea and Rest of World) Market (2010-2012) and Forecast (2013 to 2017) • Molecular Diagnostic Sales Company Wise Analysis (Roche, Abbott, Myriad Genetics, Qiagen, BioMérieux and Others ) Market (2010-2012) and Forecast (2013 to 2017) • Molecular Diagnostic and Road to Personalized medicine• Molecular Diagnostic Clinical Trial Statements (20 Clinical Trials Studied in the report)• Driving Forces & Challenges for Global Molecular Diagnostic Market

Data Sources

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.

2 of 8

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,051.73 -48.45 -0.28%
S&P 500 1,973.63 -4.59 -0.23%
NASDAQ 4,424.7040 -7.4420 -0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs